Guillaume Clerfond

Dr. Guillaume Clerfond

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
RERomain Eschalier
Romain Eschalier
GMGrégoire Massoullié
Grégoire Massoullié
YBYves Boirie
Yves Boirie
MBMarie Blanquet
Marie Blanquet
AMAurélien Mulliez
Aurélien Mulliez
GCGuillaume Clerfond
Guillaume Clerfond

6 June 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
MBMarie BLANQUET
Marie BLANQUET
GMGrégoire Massoulié
Grégoire Massoulié
YBYves Boirie
Yves Boirie
CGCandy Guiguet-Auclair
Candy Guiguet-Auclair
AMAurélien Mulliez
Aurélien Mulliez
RERomain Eschalier
Romain Eschalier

1 May 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GCGuillaume Clerfond
Guillaume Clerfond
Bruno PereiraBruno Pereira
Bruno Pereira
AIAndrea Innorta
Andrea Innorta
PMPascal Motreff
Pascal Motreff
MGMartine Gilard
Martine Gilard
GSGéraud Souteyrand
Géraud Souteyrand

5 October 2021 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
CGClarisse Grèze
Clarisse Grèze
Bruno PereiraBruno Pereira
Bruno Pereira
YBYves Boirie
Yves Boirie
LGLaurent Guy
Laurent Guy
CMClémentine Millet
Clémentine Millet
AHAnne-Elisabeth Heng
Anne-Elisabeth Heng
The access of obese patients to kidney transplantation is limited despite several studies showing that obese transplant recipients had a better survival rate than those undergoing dialysis. The aim of this study was to compare patient and graft survival rates and post-renal transplant complications in obese patients and non-obese patients and to assess the effect of pre-transplant weight loss in obese patients on transplant outcomes. We carried out a prospective cohort study using two French registries, the Renal Epidemiology and Information Network and CRISTAL, on 7270 kidney transplant patients between 2008 and 2014 in France. We compared obese patients with non-obese patients and obese patients who lost more than 10% of weight before the transplant (obese WL and obese nWL). The mean BMI in our obese patients was 32 kg/m2. Graft survival was lower in obese patients than in non-obese patients {hazard ratio (HR) = 1.40, [95% confidence interval (95% CI) 1.09; 1.78], P = 0.007}, whereas patient survival was similar [HR = 0.94, (95% CI 0.73; 1.23), P = 0.66]. Graft survival was significantly lower in obese WL than in obese nWL [HR = 2.17, (1.02; 4.63), P = 0.045], whereas patient survival was similar in the two groups [HR = 0.79, (0.35; 1.77), P = 0.56]. Grade 1 obesity does not seem to be a risk factor for excess mortality after kidney transplantation and should not be an obstacle to having access to a graft. Weight loss before a kidney transplant in these patients should not be essential for registration on waiting list.

28 February 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
GMGrégoire Massoullié
Grégoire Massoullié
BBBaptiste Boyer
Baptiste Boyer
Vincent SapinVincent Sapin
Vincent Sapin
FJFrédéric Jean
Frédéric Jean
MAMarius Andronache
Marius Andronache
RERomain Eschalier
Romain Eschalier
Background: Myocarditis is a known cause of sudden cardiac death of the athlete. The impact of direct chest trauma in at-risk sports or activities in patients with a history of myocarditis has never been demonstrated or studied. We report herein two cases of life-threatening ventricular arrhythmia secondary to non-penetrating blunt chest trauma while playing contact sports. Case summary: The first patient, a 26-year-old man described a brief loss of consciousness after having received blunt impact to the chest (typical intensity) while playing a rugby match. The loss of consciousness was total and proceeded by rapid and regular palpitations. He had a history of viral myocarditis 10 years prior with a fibrotic sequalae in the inferolateral wall on cardiac magnetic resonance imaging (left ventricular ejection fraction 71%). Right apical ventricular pacing induced a sustained monomorphic ventricular tachycardia reproducing the patient’s symptoms. A subcutaneous implantable cardioverter-defibrillator was implanted. The second patient is a 22-year-old professional rugby player with no known notable history. During a match, a direct blow to the chest wall was followed by a cardiac arrest. A ventricular fibrillation was cardioverted to pulseless electrical activity. Patient died despite cardiopulmonary resuscitation. An autopsy identified a myocardial sequela of fibrosis with no acute inflammatory remodelling compatible with a previous myocarditis. Discussion: Myocarditis may increase the risk of life-threatening ventricular arrhythmias caused by blunt impact to the chest, particularly in contact sports. Screening and prevention measures should be considered to reduce this risk.

24 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
GMGrégoire Massoullié
Grégoire Massoullié
NCNicolas Combaret
Nicolas Combaret
GSGéraud Souteyrand
Géraud Souteyrand
JSJean Pascal Salazard
Jean Pascal Salazard
Bruno PereiraBruno Pereira
Bruno Pereira
RERomain Eschalier
Romain Eschalier
The impact that post-dilatation has on the risk of experiencing conduction disorders after post-transcatheter aortic valve replacement with self-expanding valves (SE-TAVR) is unclear. We compared the rate of developing an atrioventricular (AV) high-grade conduction disorder and permanent pacemaker implantation (PPI) in post-TAVR patients undergoing post-dilatation. We enrolled patients with severe symptomatic calcified aortic stenosis (CAS) who were undergoing SE-TAVR between 1 January 2016, and 19 April 2019 at a single French center. Of the 532 patients treated with SE-TAVR, 417 subjects (78.4%) received Corevalve Evolute R and 115 subjects (21.6%) received the latest-generation Corevalve Evolute Pro valve. In total, 104/532 patients (19.5%; 21.6% with Evolute R vs. 12.2% with Evolute Pro, p = 0.024) required post-dilatation. Evolut R was associated with an increased risk of post-dilatation (odds ratio 2.1 (1.01–4.33, p = 0.046)). We did not observe any post-dilatation increases in AV or in intra- and interventricular conduction disorders. In total, 26.1% of participants needed PPI within the first 30 post-procedure days (p = 0.449). Post-dilatation was not associated with a higher PPI risk (subdistribution hazard ratio 1.033 (0.726–1.471); p = 0.857). No significant differences existed between the groups in terms of one-year mortality (10.3%; p = 0.507). Post-dilatation in SE-TAVR did not increase the rate of electrical conduction disorders and PPI in the early implantation phase. The latest generation of SE-TAVR valves was associated with less need for post-dilatation.